Learning from PD-1 Resistance: New Combination Strategies

Trends in Molecular Medicine

Volumn 22, Issue 6, 2016, Pages 448-451

  Bu, Xia ^a   Mahoney, Kathleen M ^a   Freeman, Gordon J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR;

ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHEMOTAXIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; IMMUNE DEFICIENCY; MACROPHAGE; MELANOMA; MONOCYTE; SHORT SURVEY; TUMOR IMMUNITY; UPREGULATION; GENETICS; IMMUNOTHERAPY;

EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 84965132216     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.04.008     Document Type: Short Survey

References (10)

1. Hugo W., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016, 165:35-44.
2. Giraldo N., et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 2015, 21:3031-3040.
3. Koyama S., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 2016, 7:10501.
4. Rizvi N.A., et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
5. Spranger S., et al. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
6. Hugo W., et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015, 162:1271-1285.
7. Loi S., et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. 2016, 22:1499-1509.
8. Lou Y., et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 2016, Published online February 5, 2016. http://dx.doi.org/10.1158/1078-0432.CCR-15-1434.
9. Hodi F.S., et al. Five-year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates. AACR Annual Meeting Program Abstr 2016, CT001.
10. Ebert P.J., et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 2016, 44:609-621.